News und Analysen
Incyte Stock: Breakthrough Drug Shows Promise
Incyte Corporation is poised for significant market growth following positive results from two pivotal Phase 3 trials for Povorcitinib, its oral JAK1 inhibitor targeting Hidradenitis suppurativa
Microvision WA Aktie: Krise absehbar?
Die Aktie des Lidar-Technologiespezialisten Microvision verzeichnete am 17. März 2025 einen Kursanstieg um 2,34% auf 1,31 USD. Trotz dieser positiven Tagesentwicklung bleibt die langfristige Tendenz
Teleflex Aktie: Wettbewerbssituation unverändert
Die Teleflex Aktie verzeichnete am vergangenen Freitag einen moderaten Anstieg von 0,80% und erreichte damit einen Kurs von 126,50 EUR. Diese positive Entwicklung steht im Kontrast zur schwachen
Novartis Stock: Shares Drop Amid Mixed Financial Outlook
Novartis shares experienced a notable decline on Friday at the Swiss SIX exchange, falling 0.7 percent to close at 96.25 CHF. The pharmaceutical stock opened at 96.52 CHF before touching a daily low
Roche Stock: Mixed Signals Amid 40% Recovery
Roche's stock has displayed a mixed performance in recent trading sessions. On Thursday afternoon, shares initially gained 0.5 percent to reach 304.70 CHF on the SIX Swiss Exchange, even touching a
Iridex Stock: Volatility Persists Amid Stable Fundamentals
Iridex Corporation (NASDAQ: IRIX) shares experienced significant fluctuations last week, with March 13, 2025 showing particularly volatile trading patterns. The Mountain View, California-based
ANI Stock: FDA Expands ILUVIEN Drug Approval
ANI Pharmaceuticals has achieved a significant milestone with the FDA's approval to expand its ILUVIEN medication for treating chronic non-infectious uveitis of the posterior segment (NIU-PS). This
EQS-News: STRATEC ERHÄLT VALIDIERUNG IHRER KLIMAZIELE DURCH DIE SCIENCE BASED TARGETS INITIATIVE (SBTi)
Starke Verkaufszahlen für Cresemba® (Isavuconazol) in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea aus
Allschwil, 14. März 2025
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an
EQS-News: Heidelberg Pharma passt Vereinbarung über den Verkauf von Lizenzgebühren mit HealthCare Royalty an
EQS-Adhoc: Heidelberg Pharma passt Vereinbarung über den Verkauf von Lizenzgebühren mit HealthCare Royalty an
Eli Lilly Stock: Roche Deal Threatens Market Dominance
Eli Lilly's stock is facing pressure following a strategic partnership announcement between Swiss pharmaceutical giant Roche and Danish firm Zealand Pharma. The deal, valued at up to $5.3 billion
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
A multibagger stock is one that has doubled your money or more. Peter Lynch, the highly respected investment manager who ran the Magellan Fund for 14 years, coined the term in his book, One Up on
Copper Miner Hudbay Soars 200% in a Year as One Investor Exited a $2.5 Million Position
On February 17, 2026, Orion Resource Partners disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold out its position in Hudbay Minerals (NYSE:HBM), with an estimated
SVP Sells Qorvo 8,226 Shares Worth $683,000
Frank P. Stewart, SVP, Advanced Cellular at Qorvo (NASDAQ:QRVO), reported the direct sale of 8,226 shares for a transaction value of approximately $683,000 on Feb. 17, 2026, according to a SEC Form
Here's Why Viking Therapeutics Stock Recovered and Can Soar 2026
Shares in Vikinig Therapeutics (NASDAQ: VKTX) rose by 16.5% in February, according to data from S&P Global Market Intelligence. The move helped the stock recover in 2026, and at the time of writing,
AEVIS VICTORIA SA - Infracore SA publishes audited 2025 consolidated results and AGM proposals
AMD CEO Lisa Su Believes Its Deal With Meta Platforms Will Be a Triple-Digit Billion Dollar Deal
In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other AI stocks. To learn more, check out the short video, consider subscribing, and click the special
EQS-Adhoc: Gerresheimer AG: Publication of the 2025 annual and consolidated financial statements only after March 31, 2026, exclusion from the SDAX, postponement of the Annual General Meeting
2 Growth Stocks to Hold for the Next Decade
Over the past year, Intuitive Surgical (NASDAQ: ISRG) and DexCom (NASDAQ: DXCM) have faced headwinds, and have lagged the stock market as a result. Shares of the former are down 13% over the
3 Reasons Not to Sleep on ResMed Stock
I confess: I've been sleeping on ResMed (NYSE: RMD) stock, not paying much attention to it at all. But maybe I shouldn't ignore it -- and you may not want to, either.
Here are three reasons why it's
2 Healthcare Stocks That Are Too Cheap to Ignore
Some indicators suggest that equity markets are currently overvalued. For instance, the S&P 500 Shiller CAPE ratio is near multi-year highs. In this environment, it pays to look for bargains, stocks
VALBIOTIS SA: Valbiotis raises awareness of cardiometabolic risks with the Cœur en Jeu prevention campaign
Investment Firm Sheds 384,000 Shares of VERX Stock, According to Latest SEC Filing
On February 17, 2026, Tensile Capital Management LP reported selling 384,415 shares of Vertex (NASDAQ:VERX) in the fourth quarter, an estimated $8.32 million trade based on quarterly average
AMD's Multi-Billion-Dollar AI Deal: Why GPU Revenue Could Drive Steady Gains
How can Advanced Micro Devices (NASDAQ: AMD) turn AI design wins and a multi‑billion dollar GPU deal into durable revenue, despite fierce competition from competitors? Watch the video below for key